# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $62 to $83.
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $...
Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:INSM) with a Overweight.
JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $55 to $72.
Nvidia surged 217.58% over the past year, 173.78% year-to-date. Here are eight large-cap stocks that outperformed it this past ...
Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $36 to $82.